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Tumor angiogenesis, essential for cancer development, is regulated mainly by
vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs), which are
overexpressed in cancer cells. Therefore, the VEGF/VEGFR interaction represents
a promising pharmaceutical target to fight cancer progression. The VEGF surface
interacting with VEGFRs comprises a short α-helix. In this work, helical oligopeptides
mimicking the VEGF-C helix were rationally designed based on structural analyses
and computational studies. The helical conformation was stabilized by optimizing
intramolecular interactions and by introducing helix-inducing Cα,α-disubstituted amino
acids. The conformational features of the synthetic peptides were characterized by
circular dichroism and nuclear magnetic resonance, and their receptor binding properties
and antiangiogenic activity were determined. The best hits exhibited antiangiogenic
activity in vitro at nanomolar concentrations and were resistant to proteolytic degradation.
Keywords: helical folded peptides, protein-protein interactions, Cα,α-disubstituted amino acids, VEGF-C,
angiogenesis
INTRODUCTION
Angiogenesis—i.e., the formation of new blood vasculature from the established blood vessel
network—can be associated to both physiological and pathological processes (e.g., inflammation,
tumor growth, and metastasis). Among the latter, tumor angiogenesis is essential for cancer
development, since neovascularization provides a steady supply of oxygen and nutrients,
supporting the proliferation of cancer cells (Mizejewski, 1999; Danhier et al., 2012; Johannessen
et al., 2013). For this reason, antiangiogenic agents are used to impede or retard cancer progression
and metastasis (Ferrara and Adamis, 2016).
Different receptors are involved in angiogenesis regulation, and their expression
depends on the conditions of the cell environment (e.g., pH, oxygen or supply of
nutrients) (Mizejewski, 1999). Angiogenic processes are also mediated by cross-talk
mechanisms that trigger direct association and cluster formation between specific receptors.
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For example, the cooperation between integrins
and vascular endothelial growth factor receptors
(VEGFRs) was found to be crucial in pathological
processes such as tumor growth and development
(Somanath et al., 2009; Desgrosellier and Cheresh, 2010).
VEGFRs are receptor tyrosine kinases (RTKs) that have a
central role in tumor angiogenesis and progression. Indeed,
the hypoxic conditions characteristic of the tumor environment
induce both up-regulation of VEGFRs and gene expression of
vascular endothelial growth factors (VEGFs) (Ferrara et al., 2003;
Hoeben et al., 2004; Olsson et al., 2006; Carmeliet and Jain,
2011; Shibuya, 2013). In addition to the tumor promoting effects
of neovascularization, autocrine VEGF/VEGFR signaling favors
growth, proliferation and migration of cancer cells (Su et al.,
2007; Simon et al., 2017).
Dimerization and activation of VEGFRs are triggered by
binding of VEGFs to the extracellular domain of the receptors
(Ferrara and Adamis, 2016). The VEGF family consists of five
members [VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF
(placental growth factor)], and there are three distinct receptors
(VEGFR-1, VEGFR-2, VEGFR-3). The various growth factors
have differential selectivity: for instance, VEGF-A binds to
VEGFR-1 and VEGFR-2, while VEGF-C binds to VEGFR-2
and VEGFR-3. In addition, the three receptors have different
functions, with VEGFR-2 being mainly involved in angiogenesis
and VEGFR-3 regulating lymphangiogenesis (Ferrara and
Adamis, 2016; Nasir, 2019).
Three main approaches targeting VEGF-A/VEGFR-2
signaling in human cancer have been approved for clinical
practice (Nasir, 2019). One strategy involves inhibition of
the tyrosine kinase activity of VEGFR-2 by small molecules
interacting with the intracellular segment of the receptor,
such as sorafenib and sunitinib (Musumeci et al., 2012).
Alternatively, VEGF-mediated angiogenesis can be impaired
by blocking the VEGF-A/VEGFR-2 interaction. This has been
accomplished by binding and neutralizing circulating VEGF-A
with monoclonal antibodies (bevacizumab) or recombinant
proteins mimicking the receptor (aflibercept) (Ferrara et al.,
2004; Ferrara and Adamis, 2016). Alternatively, VEGFR-2
has been targeted with therapeutic monoclonal antibodies,
such as ramucirumab. These molecules are now a standard of
care for the treatment of several metastatic cancers (Ferrara
and Adamis, 2016), even though clinical results have not met
in all cancer types the initial high hopes for this therapeutic
strategy, underlining the need for more effective antiangiogenic
drugs (Vasudev and Reynolds, 2014; Ronca et al., 2017).
Anti-VEGF-A/VEGFR-2 therapy has proven more effective in
ophthalmology, in the treatment of intraocular neo vascular
disorders, such as age-related macular degeneration (Ferrara and
Adamis, 2016). However, each of the above mentioned approved
drugs has its own limitations: kinase inhibitors have limited
selectivity, while antibodies suffer from poor pharmacokinetics,
limited tissue penetration and high costs (Chames et al., 2009;
Howard et al., 2015). Their use in the therapy of eye diseases
requires repeated intravitreal injections, and new drugs that
can be administered by simpler and safer routes are highly
desirable (Sidman et al., 2015).
Peptides and peptidomimetics with a well-defined
conformation (foldamers) represent a promising alternative
to biological therapeutics for the inhibition of protein-protein
interactions, and are currently experiencing a revival of interest
from the pharmaceutical industry (Henninot et al., 2018).
Among those able to interact with the extracellular domain of
VEGFRs, it is worth mentioning the peptoid ligands described
by Kodadek and colleagues (Udugamasooriya et al., 2008), the
helical peptides developed starting from VEGF-A and Vammin
hotspots (García-Aranda et al., 2013), and cyclopeptides isolated
by phage display technique (Zilberberg et al., 2003), or rationally
designed (Gautier et al., 2010). In 2011, D’Andrea and coworkers
developed a α-helical decapentapeptide based on the natural
sequence of VEGF-A, with potent inhibitory activity against
VEGF-stimulated angiogenesis in vivo (Basile et al., 2011;
Diana et al., 2013). Because of its synthetic accessibility and
antiangiogenic properties, recently some of us selected that
peptide to prepare a dual-action compound able to interfere
with the integrin αVβ3-VEGFR-1 cross-talk (Zanella et al., 2015).
This conjugate was able to bind in vitro both integrin αVβ3
and VEGFR-1, and exerted a strong antiangiogenic effect in
VEGF-stimulated morphogenesis assays on human umbilical
vein endothelial cells (HUVECs).
Herein, we report the results of our efforts to develop new
VEGFR antagonists based on a helical fragment of VEGF-C, with
promising activity against VEGF-mediated angiogenesis.
RESULTS
Design
A Short Helix Is an Important Element of the
VEGF/VEGFR Interface
The extracellular domain of VEGFRs consists of seven Ig
homology domains. VEGF binding takes place mostly on domain
D2. Figure 1 shows the structure of the VEGF-A/VEGFR-1 (D2
domain) interface, whose main features are conserved in all
VEGF/VEGFR complexes (Leppänen et al., 2013). We started
our analysis from this complex, because all currently approved
antiangiogenic drugs are targeted to VEGF-A or to VEGFR-1.
VEGF residues are colored from green to red in order of
increasing penalty in the standard binding free energy caused
by their substitution to Ala, as predicted by in silico alanine
scanning. This analysis indicates that a short helix, located at the
N-terminal region of the growth factor, represents a significant
portion of the interaction interface. Previous experimental
studies have shown that this helix is involved in receptor
specificity and protein dimerization of VEGFs (Siemeister et al.,
1998; Robinson and Stringer, 2001; Leppänen et al., 2010). In
the case of VEGF-A, the helix comprises residues 17–25 (a
nonapeptide).Table 1 reports the numerical results of the in silico
Ala scan for those residues, showing that the interaction with
the receptor is mediated principally by amino acid residues at
positions 1, 2, 5, 6, and 9 of the helical nonapeptide. This finding
is consistent with experimental Ala scan data (Muller et al., 1997;
Li et al., 2000). A similar analysis performed on the structure of
the VEGF-A/VEGFR-2 complex confirmed the N-terminal helix
as an important interacting element (Figure S1).
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FIGURE 1 | Structure of a VEGF/VEGFR complex (PDB code 1FLT). Ig-homology domain 2 of the receptor (VEGFR-1) is shown in surface representation (light blue
and blue for the two subunits), while the two subunits of VEGF-A are shown as ribbons of two different shades of green. VEGF residues are colored depending on the
standard binding free energy penalty associated with their mutation to Ala, as predicted by DrugScorePPI (values from 0 to 1.5 kcal/mol are reported in shades of
color going from green to red; values 1.5 kcal/mol and above, up to the maximum of 2.4 kcal/mol, are all reported in red).
TABLE 1 | In silico Ala scan of the VEGF-A helix interacting with VEGFR-1 (PDB
code 1FLT)a.
Position
in the
Residue FoldX DrugScorePPI KFC2 PCRPi
helix 11G◦
binding
(kcal/mol)
11G◦
binding
(kcal/mol)
Hot spots Probability (%)
1 Phe 17 1.6 0.4 X 48
2 Met 18 2.0 0.4 X 8
3 Asp 19 0.1 – – 0
4 Val 20 0.1 – – 0
5 Tyr 21 2.4 2.4 X 14
6 Gln 22 0.7 0.3 – 2
7 Arg 23 0.2 0.1 – 0
8 Ser 24 0.2 – – 0
9 Tyr 25 0.5 1.4 X 4
aFoldX and DrugScorePPI predict the penalty in standard binding free energy for
substitution of each residue to Ala, the KFC2 server simply predicts hotspots and PCRPi
reports the probability that a given residue is a hotspot. Substitutions that are predicted
to have a strong effect on the binding are colored in red (i.e., those with a v 11G◦binding
higher than 1.0 kcal/mol or indicated by KFC2 as hot spots or with a PCRPi probability
greater than 10). Substitutions that are predicted to have a mild effect on the binding are
colored in light red (i.e., those with 11G◦binding comprised between 0.3 and 1.0 kcal/mol
or with a PCRPi probability comprsed between 1 and 10)
The Helix of VEGF-C Presents the Most Promising
Inter- and Intra-molecular Interactions
Figure 2 shows the corresponding helical sequences in various
growth factors, together with the available crystallographic
structures of their complexes with receptors. In most cases, the
interaction is largely based on hydrophobic effects. The only
significant exception is provided by VEGF-C, which forms an
intermolecular salt bridge with Arg164 of VEGFR-2 through the
Asp residue at position 2 of the helix. This specific interaction
is predicted to improve the selective recognition of the VEGF-C
helix by VEGFR-2. Figure S1 shows the results of an in silico Ala
scan performed on the VEGFR-2/VEGF-C complex, confirming
the centrality of the N-terminal helix in the recognition process.
The VEGF-C helix presents also another interesting property.
Short helical segments are usually largely disordered when
separated from the protein that contained them. Without the
stabilization provided by the rest of the protein structure,
competition by water molecules breaks the intramolecular
H-bond network that holds the helical conformation together.
On the other hand, binding to the receptor requires a helical
conformation. Therefore, a disordered peptide pays a significant
entropic cost for association to the receptor. Thus, stabilization
of the helical conformation in such short peptides is advisable.
Interestingly, the helix of VEGF-C presents three pairs of side
chains that potentially form interactions stabilizing a helical
conformation, being located at an i - i+3 or i - i+4 distance. In
particular, Ile1 and Trp5 can form a hydrophobic cluster, while
both Asp2 and Arg6 and Glu4 and Lys7 can form salt bridges
(numbers correspond to positions in the helix).
Replica exchange molecular dynamics (REMD) simulations
were used to verify the stability of the VEGF-C helix, when
free in solution. Figure 3 reports the secondary structure of the
peptide, a representative conformation and the histograms of the
distances between the side-chains mentioned above during the
simulation trajectory. The data confirm that the ion pairs and
hydrophobic cluster are significantly populated and stabilize the
helical conformation of the peptide in solution.
For all these reasons, we decided to focus on the VEGF-C
helix sequence (peptide 1) (Figure 4) to develop VEGF/VEGFR
interaction inhibitors.
Substitution of Two Residues in the VEGF-C
Sequence Is Predicted to Increase Binding Affinity
In order to optimize peptide affinity for VEGFRs, in silico
mutagenesis was performed, concentrating on the VEGF-
C/VEGFR-2 complex (PDB code 2X1X). All residues of the helix
previously identified as hot spots were mutated to all possible
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FIGURE 2 | Structures of the helix-interacting interface in VEGF/VEGFR receptor complexes. The receptor is shown in light blue and the growth factor helix in green.
The following crystallographic structures were used: 1FLT for VEGF-A/VEGFR-1, 3V2A for VEGF-A/VEGFR-2, 2XAC for VEGF-B/VEGFR-1, 2X1X for
VEGF-C/VEGFR-2, 4BSK for VEGF-C/VEGFR-3, 3VSB for VEGF-E/VEGFR-2, 1RV6 for PlGF/VEGFR-1. Sequences of the helix correspond to residues 17–25 for
VEGF-A, -B and -E, residues 122–130 for VEGF-C, and residues 25–33 for PlGF. In the sequences, reported on top in the single letter code, interacting residues are
underlined, bolded, and colored, according to the following code: green, purple, red, and blue for hydrophobic, polar, anionic, and cationic residues, respectively. The
ion bridge formed in the VEGF-C/VEGFR-2 complex is indicated by a purple line.
coded amino acids, evaluating the effect of the substitution on the
standard binding free energy. This analysis identified substitution
of the first residue from Ile to Trp, and of the last one from Gln to
Trp or Val as the only mutations that would lead to a significant
predicted improvement in standard binding free energy (>1
kcal/mol). Either hydrophobic substitution at position 1 would
maintain the helix-stabilizing cluster identified above, but Trp
has a higher intrinsic helix propensity than Ile (Chakrabartty
et al., 1994; Pace and Scholtz, 1998). Based on these findings,
sequence 2 was designed (Figure 4). Figure 5 shows how the N-
and C-terminal Trp residues increase the interactions between
helix and receptor.
A more comprehensive computational analysis on
the proposed substitutions, carried out by molecular
mechanics—Poisson Boltzmann surface area calculations
(MM-PBSA) (Hou et al., 2010), confirmed the prediction,
showing that the presence of Trp residues at each peptide
terminus should indeed lead to an increased binding
affinity (Table 2).
Cα,α-Disubstituted Amino Acids Can Be Inserted to
Increase Peptide Helicity and Stability
Cα,α-disubstituted α amino acids strongly stabilize helical
structures: due to steric interactions between the gem alkyl
and methyl groups linked to the α-carbon, the accessible
conformational space of such residues is extremely limited and
is located in the region of the Ramachandran plot corresponding
to helical structures. For this reason, such Cα,α-disubstituted
amino acids constitute suitable building blocks to synthesize
oligopeptide with a stable helical folding (Toniolo et al., 2001).
In addition, insertion of non-proteinogenic amino acids strongly
reduces peptide susceptibility to proteolysis (De Zotti et al.,
2009). The simplest and most studied Cα,α-disubstituted amino
acid residue is α-amino isobutyric acid or Aib. Aib is a natural
amino acid featuring two methyl groups on its α-carbon. It
is non-ribosomally included in peptide sequences by fungal
synthases. This achiral residue is a well-known helix inducer.
One peptide sequence modified to include Aib is the well-
known commercial drug semaglutide (Al Musaimi et al., 2018).
Positions not involved in the interaction (i.e., 3, 4, 7, and 8 in
the helix, see above) were considered for possible modifications.
Position 2 was analyzed as well, as the Cα,α-disubstituted
amino acids analogue of Asp, α-methyl-aspartic acid (α-Me)Asp,
is commercially available. Although literature reports on the
conformational properties of this specific residue are lacking,
the preference for helical conformations is a common feature of
methyl-containing disubstituted residues, and its homologue (α-
Me)Asn was reported to promote type III β turn (i.e., a portion
of a 310 helix) in short peptides (Hopkins et al., 2000). Analysis
of the structure of the VEGF-C/VEGFR-2 complex showed that
addition of a methyl group on the alpha carbon at these positions,
or addition of a residue at the N-terminus, would not cause any
intermolecular clashes.
Based on these considerations, four analogues were designed,
based on sequence 2 (Figure 4). In analogues 5 and 6, Glu4 was
substituted by (α-Me)Asp, and Lys7 by the cationic amino acid
Api (4-aminopiperidine-4-carboxylic acid). Such cyclic residue
can promote a helical conformation to some extent when
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FIGURE 3 | Stability of intramolecular interactions and secondary structure in
the REMD simulation of peptide 1 (300K replica). Upper: distributions of the
minimum distances between the charged groups of Asp123 and Arg127 (red)
and of Glu125 and Lys128 (orange) and between the side chains of Ile122 and
Trp126 (green). Residue numbers refer to the VEGF-C sequence. The first ns
of the simulation was excluded from the analysis. Lower: secondary structure
according to DSSP. Blue: alpha helix, grey: 310 helix, yellow: turn, green:
bend, white: coil.
incorporated into peptides (Cho et al., 2010; Dalzini et al., 2016).
In addition, in peptide 5 Asp2 was substituted by (α-Me)Asp,
too, while in 6 an Api residue was added at the N-terminus.
In analogue 4, Aib was inserted at positions 4 and 8, and
also added at the N-terminus. For comparison, analogue 3 has
been synthesized, with the same sequence of 4, but without the
Trp substitutions.
Synthesis of VEGF-C Derived Peptides 1-6
Peptide sequences 1–6 (Figure 4) were conveniently prepared
by solid-phase peptide synthesis (SPPS) on Rink Amide
4-methylbenzhydrylamine (MHBA) resin using the 9-
fluorenylmethoxycarbonyl/t-butyl ether (Fmoc/tBu) strategy.
Each step of the SPPS was performed with a semi-automatic
synthesizer, assisting coupling reactions with microwaves.
First, the resin was swelled in dimethylformamide (DMF) and
treated with a 25% solution of piperidine in DMF to remove the
Fmoc-protecting group, releasing the reactive amino moiety on
the beads (step a). The Fmoc-amino acid to be attached to the
solid support was activated with N,N′-diisopropylcarbodiimide
(DIC) and 1-hydroxy-7-azabenzotriazole (HOAt) coupling
reagents in the presence ofN,N-diisopropylethylamine (iPr2NEt)
in DMF: after stirring for 25min at 0◦C, the mixture was added
to the resin and a cycle of coupling, capping and deprotection
was performed (step b). This procedure was repeated until
the sequence was completed, then the N-terminal residue was
acetylated and the beads were treated with TFA in the presence of
thioanisole, 1,2-ethanedithiol (EDT) and anisole as scavengers.
Subsequent purification of the crude peptide with reversed
phase high-performance liquid chromatography (RP-HPLC) and
freeze-drying from glacial acetic acid gave the pure compound as
a fluffy solid.
Due to the high steric congestion, α,α-disubstituted residues
are poorly reactive even after activation. For this reason, the
coupling reaction was performed twice whenever a quaternary
amino acid had to be attached to the resin: according to this
synthetic protocol, after the first coupling step, a second aliquot of
the activated quaternary amino acid was added to the resin and
another condensation reaction was carried out. This procedure
allowed to minimize the number of unreacted amino moieties on
the beads.
Further details are provided in the Supplementary
Information (Figures S2–S14, Tables S1–S6, Scheme S1).
Structural Investigation
Circular dichroism (CD) experiments in water demonstrated
that all analogues populate helical conformations in solution
to some extent, as predicted by REMD simulations for the
natural sequence 1. As shown in Figure 6, the positive peak
at approximately 190 nm, and the negative bands at about 205
and 220 nm, typical of helical structures, are present in the
spectra of all analogues (Kelly and Price, 1997). Quantitative
determinations of the degree of helicity is complicated by the
presence of multiple aromatic residues, whose side-chains can
contribute significantly to the CD in the far UV region. However,
several features indicate that analogues 5 and 6 are more helical
than the other peptides: compared to the spectra of analogues
1–4, the positive peak is higher, the negative band at short
wavelengths is red-shifted and the ratio of the two negative bands
at approximately 220 and 205 nm is closer to one (Kelly and
Price, 1997). Actually, for 5 this ratio is even higher than one,
possibly indicating that some peptide aggregation is taking place
(Dai et al., 2004). A stabilizing effect of the introduced Cα,α-
disubstituted amino acids was less obvious in the spectra of
analogues 3 and 4.
In near UV CD spectra, the induced dichroism band of
Trp was more intense for analogues 3–6 than for peptides 1
and 2, which comprise coded amino acids only. This finding
indicates that the Cα,α-disubstituted amino acids rigidified the
helical conformation. To confirm this conclusion also in the
case where far UV CD spectra were less informative, analogues
1 and 3 were directly compared in 2D nuclear magnetic
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FIGURE 4 | Sequences of the VEGF-C natural portion 1 and of the derived peptides 2–6. Sequences are colored in green, purple, red, and blue for hydrophobic,
polar, anionic, and cationic residues. The introduced modifications are underlined.
FIGURE 5 | Structures of peptides 1 (left) and 2 (right), interacting with VEGFR-2. The structure of peptide 1 was taken from the VEGF-C structure (PDB code
2X1X), while that of peptide 2 was modeled with FoldX.
TABLE 2 | Results of the MM-PBSA calculations of the interaction of peptides 1
and 2 with VEGFR-2a.
Peptide 1Epot
(kcal/mol)
1G◦ PB
(kcal/mol)
1SAS
(nm2)
1G◦binding
(kcal/mol)
1 −32 ± 1 26 ± 1 −3.59 ± 0.02 −8 ± 2
2 −39 ± 1 27 ± 1 −4.42 ± 0.02 −14 ± 2
aThe various terms are described in the Methods section.
resonance (NMR) measurements in water (Figure 7). For both
peptides, all sequential NH-NH cross peaks were present in the
ROESY (Rotating-frame nuclear Overhauser Effect correlation
SpectroscopY) spectrum, indicating the onset of a helical
structure. However, the spectra did not show any long range
connectivity for 1, while the presence of two long-range cross-
peaks (Asp3HA-Aib5HN and Trp6HA-Aib9HN) for peptide 3,
including an αHi → NHi+2 interaction, is a clear indication that
this analogue adopts a well-developed 310-helical conformation
in water.
Overall, these data indicate that the introduction of Cα,α-
disubstituted amino acids stabilized the helical conformations,
particularly in analogs 5 and 6, where chiral (α-Me)Asp residues
were inserted in the sequence.
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FIGURE 6 | CD spectra of the peptides in distilled H2O (10
−4 M), in the far UV (left) and near UV (right).
FIGURE 7 | 2D proton NMR ROESY spectra in H2O:D2O 9:1 (600 MHz, 298K) for compounds 1 (left) and 3 (right) (concentrations 1.1 and 1.4 mM, respectively).
Top panels report NH-NH sequential correlations, while the bottom panels correspond to the fingerprint region showing long-range αH-NH correlations. In the case of
compound 3, long range cross-peaks, including the αHi → NHi+2 diagnostic of 310-helical structures, are highlighted in blue.
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Biological Studies
Inhibition of VEGF-A/VEGFR-1 Complex Formation
in vitro
A chemiluminescent assay to determine the inhibition of
complex formation between VEGF-A (isoform VEGF165) and
the extracellular domain of VEGFR-1 (Goncalves et al., 2007;
García-Aranda et al., 2013) had been previously employed in
our group (Zanella et al., 2015). VEGF-C (from which analogue
1 was derived) is not selective for VEGFR-1 (Su et al., 2007),
but unfortunately the same assay protocol turned out to be
ineffective with VEGFR-2, at least in our hands. The assay based
on VEGFR-1 was therefore applied here as a very stringent test
of the affinity of our peptides for VEGFRs, and to assess the
different peptides comparatively. All peptides were able to inhibit
complex formation (Table 3), although in the high micromolar
range. The introduction of quaternary amino acids resulted in
a beneficial effect in terms of affinity toward VEGFR-1, with
analogs 3, 5 and 6 being the most effective. Further studies
were focused on analogues 5 and 6, considering also the higher
stability of their secondary structure, which affects resistance to
proteolytic degradation.
Resistance to Proteolytic Degradation
Peptides 5 and 6 were very stable against proteases, presumably
thanks to the presence of non-natural amino acids in their
sequences and to their stable secondary structure. HPLC analysis
(Figures S15–S24) demonstrated that peptide 5 was fully stable
to trypsin, chymotrypsin and pronase for 90 minutes and it
persisted even after many days, although some degradation was
slowly occurring. Peptide 6 was fully stable even after 6 days. By
contrast, the natural sequence 1 was degraded within 15min by
all three enzymes.
Inhibition of HUVEC Morphogenesis
The ability of peptides 5 and 6 to affect neovessel formation
in vitrowas investigated on HUVECs according to the previously
reported procedure (Fanelli et al., 2014). Experiments were
performed in the presence of peptide 5 or 6 under resting
(absence of stimuli) or stimulated (VEGF165) conditions. As
expected, under resting conditions, HUVECs did not show any
significant network formation, while the presence of VEGF165
induced a strong increase in loop and branches formation
(Figure 8). Pre-incubation with either 5 or 6 significantly
reduced VEGF165-induced loop and branches formation and
TABLE 3 | Inhibition of biotinylated VEGF165 binding to isolated VEGFR-1.
Peptide % Inhibitiona
1 27 ± 1
2 29 ± 7
3 86 ± 1
4 40 ± 10
5 82 ± 1
6 83 ± 3
a% of inhibition of biotinylated VEGF165 binding to VEGFR-1 at 500 µM.
this effect was concentration-dependent, reaching statistical
significance at 10 nM for loop and 1 µM for branches formation
(Figure 8). Interestingly, these values are much lower than the
concentrations needed to inhibit VEGF-A/VEGFR-1 association,
possibly indicating a significant selectivity toward VEGFR-2. It is
worth noting that inhibition of loop formation was more marked
for analogue 5 than for 6, at all concentrations tested.
DISCUSSION
Several peptides able to bind to VEGFRs have been reported in
the literature. Some of them were identified by library screening
or phage display approaches, while others were developed by
rational design, reproducing different epitopes of the VEGFR
interacting surface of VEGFs. However, most of these studies
were focused on mimicking VEGF-A, which is traditionally
considered themaster regulator of angiogenesis throughVEGFR-
2 binding (Ferrara and Adamis, 2016). In particular, all helical
foldamers mimicking the N-terminal helix were developed
based exclusively on the interacting elements of VEGF-A, i.e.,
hydrophobic residues only. Examples include the MA peptide
(Diana et al., 2013) and peptides developed by Pérez De Vega
and coworkers (García-Aranda et al., 2013; Balsera et al., 2017).
Due to their hydrophobic driving force for association, these
peptides are prone to selectivity issues, since binding sites for
amphipathic helical peptides are extremely common at protein-
protein interfaces (Bonache et al., 2014). It is also worth
mentioning that some of the peptides modeled on the VEGF-
A helix exhibited pro-angiogenic, rather than anti-angiogenic,
activity (De Rosa et al., 2018)
In the present study, from an analysis of the available
crystallographic structures of VEGFs/VEGFRs complexes, we
noted that the same helix in VEGF-C exhibits several interesting
features, including an intermolecular salt bridge with VEGFR-
2, and multiple intramolecular helix-stabilizing interactions. For
these reasons, we focused our study on the VEGF-C sequence.
VEGF-C binds to both VEGFR-2 and VEGFR-3 (Su et al.,
2007; Leppänen et al., 2010; Chen et al., 2013; Wang and
Tsai, 2015). Traditionally, regulation of lymphangiogenesis
through association with VEGFR-3 has been considered its
prevalent activity. Indeed, VEGF-C expression is closely related
to lymphangiogenesis and lymphatic metastasis in a variety of
human tumors (Chen et al., 2013). However, more recently,
VEGF-C has been demonstrated to play an important role also
in the regulation of physiological and pathological angiogenesis
(Chen et al., 2013). In addition, it has fundamental functions in
the autocrine signaling of cancer cells. VEGF-C is expressed in
a number of human malignancies, and high levels of expression
correlate with poor prognosis (Chen et al., 2013). Autocrine
VEGF-C signaling regulates cell invasion, proliferation, and
resistance to chemotherapy (Su et al., 2007). VEGF-C can
also modulate the immune system so that tumor cells more
easily escape immune surveillance (Wang and Tsai, 2015). A
very recent, groundbreaking article (Michaelsen et al., 2018;
Niclou, 2018), identified VEGF-C, rather than VEGF-A, as the
main responsible for autocrine VEGFR-2 activation and cell
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FIGURE 8 | Antiangiogenic activity of analogues 5 and 6. The images are representative phase contrast photomicrographs of HUVECs plated on Matrigel under
resting conditions (lower left) or after stimulation with VEGF165, 10 ng/mL (upper left); the effect of VEGF on loop formation, in comparison to medium alone, is clearly
evident in the upper panel. 5 (upper panels) and 6 (lower panels) were added at different concentration on VEGF-stimulated cells; both 5 and 6 are able to reduce, in a
concentration-dependent manner, the ability of VEGF to induce loops formation. The graphs describe the effect of addition of 5 (purple) and 6 (green) on
VEGF-induced neovessel formation measured as total number of loops (left graph) or total branch length (right graph). Data are expressed as mean ± SEM of 5
separate experiments. Asterisks indicate significant differences with respect to the positive control (basal medium + VEGF), with p < 0.05, according to a two-tailed
paired t-test. Negative controls (basal medium only) are also shown.
proliferation in glioblastoma. In this study, VEGF-C silencing
was superior to bevacizumab therapy in improving tumor
control. Interestingly, bevacizumab treatment increased VEGF-
C expression (Michaelsen et al., 2018), and up-regulation of
VEGF-C has been observed in tumor cells that have acquired
resistance to anti-VEGF-A therapy (Wang and Tsai, 2015),
suggesting that VEGF-Cmay compensate for VEGF-A depletion.
For all these reasons, molecules inhibiting VEGF-C signaling,
rather than, or in addition to VEGF-A interactions, might find
important therapeutic applications. In principle, our peptides,
based on the VEGF-C helix, can compete with both growth
factors for binding to the receptors.
The VEGF-C nonapeptide helix sequence has some intrinsic
helix propensity, but CD and NMR studies demonstrated
that insertion of Cα,α-disubstituted amino acids led to
a significant stabilization of the secondary structure. In
particular, analogues 5 and 6, containing the chiral (α-
Me)Asp amino acids, had a more stable helical conformation
than peptides 3 and 4, where achiral Aib residues were
introduced. Peptides comprising these modifications were
highly resistant to proteolytic degradation, and stabilization
of the helical conformation probably contributed to favor
receptor binding, by reducing the entropic cost of the association
process. Indeed, these molecules were able to bind even
receptor VEGFR-1, where specific ion-pair interactions are
not possible, although in the high micromolar range. More
importantly, they inhibited VEGF-induced morphogenesis in
the low nM range, possibly through their interaction with the
VEGFR-2 receptor.
One point worth mentioning is that the N-terminal VEGF
helix, mimicked by our peptides, is involved also in the interface
of the growth factor dimer (see Figure 1). Therefore, inhibition
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of VEGF dimerization could contribute to the antiangiogenic
activity of the compounds developed here.
Further studies are warranted to characterize the interaction
of the designed peptides with different VEGFRs and the
molecular mechanisms of their antiangiogenic activity. However,
our data clearly indicate that the development of antiangiogenic
folded synthetic peptides inspired by the VEGF-C N-terminal
helix might open the way to a novel class of anticancer agents.
METHODS
In silico Mutagenesis
in silico alanine scanning was performed with FoldX 4.0
(Schymkowitz et al., 2005) and the DrugScorePPI (Krüger and
Gohlke, 2010), KFC2 (Zhu and Mitchell, 2011), and PCRPi
(Segura Mora et al., 2010) servers. In silico mutagenesis was
performed with FoldX, by first repairing the PDB file (PDB code
2X1X), then introducing themutations and finally calculating the
complex standard binding free energy, and subtracting the value
of the WT complex. Structural images were obtained using the
Chimera software (Pettersen et al., 2004).
Molecular Dynamics Simulations
Molecular dynamics (MD) simulations were carried out by using
the GROMACS 4.6.3 software package (Hess et al., 2008). The
ff53a6 parameters (Oostenbrink et al., 2004) were adopted for
the complexes and the SPC model (Berendsen et al., 1981)
was used for the water molecules. Short-range electrostatic
interactions were cut-off at 1.2 nm and long range electrostatic
interactions were calculated using the particle mesh Ewald (PME)
algorithm (Essmann et al., 1995). Simulations were run with
a 2 fs time step. The Berendsen algorithm was used to keep
temperature and pressure constant (Berendsen et al., 1984). Bond
lengths were constrained with the LINCS algorithm (Hess et al.,
1997). The structure with PDB code 2X1X from the Protein
Data Bank was used as a starting point for the simulations.
After solvating the proteins with roughly 6500 water molecules
and an opportune number of Na+ and Cl− ion to ensure
electroneutrality in a box of about 180 nm3, the potential energy
of the systems was minimized. A multi-step procedure was
adopted for equilibration, first constraining both the protein
and the peptide, then releasing the constraints on the peptide
conformation, and finally removing all constraints. In each step,
the temperature was gradually raised from 50K to 300K in 8 ns,
and the conformation with the most favorable peptide-protein
interaction energy was selected as the starting structure for the
successive step. Finally, 50 ns production runs were performed.
MM-PBSA Calculations
The protein-peptide binding energies were obtained from MD
simulations by using the MM-PBSA protocol. The binding free
energies were calculated according to the following equation
1G◦binding = G
◦
complex − G
◦
receptor − G
◦
ligand
In these free energy values, the potential energy terms
were obtained by using the GROMACS g_energy tool. The
electrostatic solvation terms were calculated with the APBS
software (Baker et al., 2001). The dielectric constant was set equal
to 78.54 for water and 2 for the solute. The input files for APBS
were generated with the PDB2PQR server (Dolinsky et al., 2004).
The non-polar solvation energies were computed as
G◦surf = γ SAS
in which γwas set equal to 0.543 kcalmol−1 nm−2 (Fogolari et al.,
2003), solvent accessible surface (SAS) values were obtained by
using the g_sas tool of GROMACS.
REMD Simulations
REMD simulations were performed using the GROMACS
software package. An extended conformation was used as the
starting structure. After minimization and equilibration, 16
replicas were simulated with temperatures ranging from 260 to
650K, chosen to ensure an exchange probability between replicas
equal to 55% (Patriksson and van der Spoel, 2008); exchanges
were attempted every 2 ps and the simulation time of each
replica was 50 ns. The Amber FF99-SB parameters were used to
describe the peptide (Hornak et al., 2006) and theOBC (Onufriev,
Bashford, and Case) GBSA implicit solvent model (Onufriev
et al., 2004) was used to mime the solvent. Bond lengths were
constrained with the SHAKE algorithm (Ryckaert et al., 1977)
and simulations were run with a 2-fs time step. Temperatures
were kept constant by using the velocity-rescale algorithm (Bussi
et al., 2007). Secondary structure was assigned by means of
Dictionary of Protein Secondary Structures (DSSP) (Kabsch and
Sander, 1983). The g_mindist tool in GROMACS was used to
calculate the minimum distances between groups of atoms.
SPPS
Semi-automatic SPPS was accomplished through the Biotage R©
InitiatorTM synthesizer, assisted by microwave (MW) irradiation;
Fmoc/tBu strategy and Rink Amide MHBA Resin (100–200
mesh; loading: 0.5 mmol/g) were used. Peptides were obtained
with yields up to 30% and purities between 97% and >99%.
Refer to the Supporting Information for a detailed description of
materials, procedures, and methods.
CD
Jasco J-715 (Tokyo, Japan) spectropolarimeter—equipped with a
Haake thermostat (Thermo Fisher Scientific, Waltham, MA)—
was used to collect circular dichroism spectra. Bidistilled water
was used as solvent. Fused quartz cells of either 1 or 10mm
pathlength (Hellma, Mühlheim, Germany) were used. Spectra
were baseline subtracted as expressed in terms of [θ]T, total molar
ellipticity (deg× cm2 × dmol−1).
NMR
2D-NMR experiments for conformational studies were
carried out on a Bruker Avance DMX-600 instrument,
using TOPSPIN 1.3 software package. For peptide 3,
COSY (COrrelation SpectroscopY), CLEAN-TOCSY
(TOtal Correlation SpectroscopY), and ROESY spectra
(all with watergate for water suppression) were acquired.
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COSY was phase sensitive. TOCSY spectrum (spin-lock
pulse, 70ms) was acquired by collecting 400 recordings
of 76 scans each. For the ROESY spectrum (200ms
mixing time), 512 experiments, each one consisting
of 80 scans, were acquired. The full assignment was
achieved exploiting the procedure proposed by K.
Wüthrich (Wüthrich, 1986).
Inhibition of VEGF/VEGFR Complex
Formation in vitro
The chemiluminescent screening assay for the detection
of VEGFR-1 ligands was accomplished according to
the procedure described in the Supporting Information.
Unlabeled VEGF165, employed as reference compound,
showed an IC50 value of 146 pM (Zanella et al.,
2015), comparable with the previously reported value
(Goncalves et al., 2007).
Inhibition of HUVEC Morphogenesis
To assess angiogenic activity, HUVECs (2.5 × 104 cells)
were seeded in a 24-well plate coated with 100 µL/well of
Matrigel previously polymerized for 1 h at 37◦C. Cells were
then incubated for 5 h at 37◦C in a moist atmosphere of
5% CO2. The experiments were performed without or in the
presence of 5 and 6 under either resting (absence of stimuli, cell
cultured in EndoGRO medium alone, without FBS and all the
growth factors) or stimulated conditions (addition of VEGF165,
10 ng/mL). Network formation was evaluated by phase-contrast
microscopy using a fluorescence microscope (AxioVert 40CFL,
Carl Zeiss S.p.A. Milan, Italy). Five photos of each well were
recorded with 10X magnification. Network formation was finally
quantified in terms of mean number of loops per field as
topological parameters and the total length of the branches.
For the purpose of the analysis, loops were defined as any
complete ring formed by HUVECs, while open ramifications
were considered as branches. The analysis of the images was
performed using the free software ImageJ (https://imagej.nih.
gov/ij/).
Resistance to Proteolytic Degradation
The proteolytic stability of peptides 1, 5, and 6 was assessed
against three enzymes: pronase, trypsin and chymotrypsin
(Sigma-Aldrich). Each peptide was dissolved in the appropriate
buffer [i.e., (2-amino-2-hydroxymethyl-propane-1,3-diol
(Tris)·HCl 20 mM, containing 20 mM CaCl2 pH 7.6 for pronase;
Tris·HCl 50 mM, pH 7.8 for trypsin and chymotrypsin). Then,
it was incubated with and without the enzyme solution (1.25
µg of enzyme in 150mL buffer) at 37◦C for 12 h. The mixture
was analyzed by RP-HPLC (column: Phenomenex Jupiter 5µ
C18 300 Å) every ten minutes for the first hour, then every half
hour. Gradients: 5–25%B in 10min for peptide 1; 15–35%B in
10min for peptide 5; 15–25%B in 10min for peptide 6. Eluants:
A, H2O:CH3CN 9/1 + 0.05% trifluoroacetic acid (TFA); B:
CH3CN:H2O 9/1+ 0.05% TFA.
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